XML 66 R43.htm IDEA: XBRL DOCUMENT v3.22.0.1
GOODWILL AND OTHER INTANGIBLES (Tables)
 12 Months Ended
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of changes in the carrying amount of goodwill
Changes in the carrying amounts of our goodwill for the years ended December 31, 2021 and December 31, 2020 were as follows (in thousands):
Branded PharmaceuticalsSterile InjectablesGeneric PharmaceuticalsInternational PharmaceuticalsTotal
Goodwill as of December 31, 2019$828,818 $2,731,193 $— $35,173 $3,595,184 
Effect of currency translation— — — (2,387)(2,387)
Goodwill impairment charges— — — (32,786)(32,786)
Goodwill as of December 31, 2020$828,818 $2,731,193 $— $— $3,560,011 
Goodwill impairment charges— (363,000)— — (363,000)
Goodwill as of December 31, 2021$828,818 $2,368,193 $— $— $3,197,011 
The carrying amounts of goodwill at December 31, 2021 and December 31, 2020 are net of the following accumulated impairments (in thousands):
Branded PharmaceuticalsSterile InjectablesGeneric PharmaceuticalsInternational PharmaceuticalsTotal
Accumulated impairment losses as of December 31, 2020$855,810 $— $3,142,657 $546,251 $4,544,718 
Accumulated impairment losses as of December 31, 2021$855,810 $363,000 $3,142,657 $550,355 $4,911,822 
Schedule of other intangible assets
Changes in the amounts of other intangible assets for the year ended December 31, 2021 are set forth in the table below (in thousands). This table excludes changes related to assets classified as held for sale to the extent such changes occurred after the assets were classified as held for sale.
Cost basis:Balance as of December 31, 2020AcquisitionsImpairmentsOther (1)Effect of Currency TranslationBalance as of December 31, 2021
Indefinite-lived intangibles:
In-process research and development$3,000 $— $— $(3,000)$— $— 
Total indefinite-lived intangibles$3,000 $— $— $(3,000)$— $— 
Finite-lived intangibles:
Licenses (weighted average life of 14 years)
$439,230 $4,177 $(1,300)$— $— $442,107 
Tradenames6,409 — — — — 6,409 
Developed technology (weighted average life of 11 years)
6,442,734 — (6,511)(212,043)1,959 6,226,139 
Total finite-lived intangibles (weighted average life of 12 years)
$6,888,373 $4,177 $(7,811)$(212,043)$1,959 $6,674,655 
Total other intangibles$6,891,373 $4,177 $(7,811)$(215,043)$1,959 $6,674,655 
Accumulated amortization:Balance as of December 31, 2020AmortizationImpairmentsOther (1)Effect of Currency TranslationBalance as of December 31, 2021
Finite-lived intangibles:
Licenses$(415,193)$(4,739)$— $— $— $(419,932)
Tradenames(6,409)— — — — (6,409)
Developed technology(3,728,963)(368,168)— 212,764 (1,124)(3,885,491)
Total other intangibles$(4,150,565)$(372,907)$— $212,764 $(1,124)$(4,311,832)
Net other intangibles$2,740,808 $2,362,823 
__________
(1)Amounts include: (i) reclassification adjustments of $3.0 million for certain developed technology intangible assets, previously classified as in-process research and development, that were placed in service during the year ended December 31, 2021; (ii) the transfer, during the third quarter of 2021, of certain developed technology intangible assets with a cost basis of $213.5 million and accumulated amortization of $211.2 million to assets held for sale, as further discussed in Note 3. Discontinued Operations; and (iii) the removal of certain fully amortized developed technology intangible assets.
Schedule of future amortization expense For intangible assets subject to amortization, estimated amortization expense for the five fiscal years subsequent to December 31, 2021 is as follows (in thousands):
2022$357,119 
2023$314,955 
2024$280,325 
2025$258,660 
2026$230,644 
Schedule of intangible asset impairment charges including goodwill
During the years ended December 31, 2021, 2020 and 2019, the Company incurred the following goodwill and other intangible asset impairment charges (in thousands):
202120202019
Goodwill impairment charges$363,000 $32,786 $171,908 
Other intangible asset impairment charges$7,811 $79,917 $347,706